MTI-31

• Description :

  MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer[1].

• Product Name Alternative :

  LXI-15029

• UNSPSC :

  12352005

• Target :

  MTOR

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/mti-31.html

• Purity :

  99.98

• Solubility :

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  C[C@@H]1N(CCOC1)C2=NC3=C(C=CC(C4=CC(C(NC)=O)=CC=C4)=N3)C(N5C6CCC5COC6)=N2

• Molecular Formula :

  C26H30N6O3

• Molecular Weight :

  474.55

• References & Citations :

  [1]Zhang Q, et, al. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clin Cancer Res. 2019 Jun 15;25 (12) :3630-3642. |[2]Qian J, et, al. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer. Oncotarget. 2016 Oct 11;7 (41) :67071-67086. |[3]Wang X, et, al. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes . J Control Release. 2019 Dec 28;316:381-392.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  MTOR; mTORC1; mTORC2

• CAS Number :

  [1567915-38-1]